Brinton Seashore-Ludlow received her PhD from KTH in 2012. She then did a Postdoc in the lab of Stuart Schreiber at the Broad Institute of Harvard and MIT. Her work there focused on elucidating predictors of drug response in a large-scale cell line profiling dataset. Brinton then moved to the Chemical Biology Consortium Sweden at SciLifeLab. There she developed several high throughput adaptations of the cellular thermal shift assay (CETSA). Currently Brinton holds a position as a team leader in the larger group of Olli Kallioniemi, where her research focuses on the application of functional precision medicine in ovarian cancer. She also heads the assay development and screening team at the Chemical Biology Consortium Sweden.
